Objective To explore the benefit and safety of the neoadjuvant treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer with patuzumab combined with anthracycline chemotherapy.Methods A total of 486 HER2 positive breast cancer patients who admitted,in Yuncheng Central Hospital from January 2021 to January 2022 were prospectively selected and divided into two groups:the con-trol group(n=243)and the study group(n=243)according to the random number table method.The control group received the traditional anthracycline containing chemotherapy scheme,and the study group received the neoadjuvant chemotherapy of patuzumab combined with anthracy-cline containing chemotherapy scheme.The therapeutic effects of two groups were compared,and the levels of tumor markers[carcinoembryonic antigen,cancer antigen(CA)125,CA153]were detected and recorded before and after treatment in two groups.Adverse reactions and prognosis were also recorded in two groups.Results The total effective rate of treatment in the research group was 90.12％,which was higher than that in the control group(76.15％),and the difference was statistically significant(P＜0.05).After treatment,the levels of carcinoembryonic anti-gen,CA125,and CA153 in two groups of patients were lower than those before treatment,and the differences were statistically significant(P＜0.05);the level of carcinoembryonic antigen in the study group was(1.89±0.78)pg/mL,which was lower than that in the control group[(1.89±0.78)pg/mL],and the difference was statistically significant(P＜0.05).However,there were no statistically significant differences in the levels of CA125 and CA153 between the two groups(P＞0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The recurrence rate,metastasis rate,mortality rate,and overall poor prognosis rate of the study group were 4.94％,6.58％,10.70％,and 22.22％,respectively,which were lower than those of the control group(10.29％,13.58％,22.63％,and 46.50％),and the differences were statistically significant(P＜0.05).Conclusion Pertuzumab combined with anthracycline-containing chemotherapy is an effective and safe neoadjuvant therapy for HER2-positive breast cancer patients.It can improve the effective rate of treatment,and will not bring additional adverse reactions to patients,improve the prognosis of patients.
关键词
抗体,单克隆/蒽环类/乳腺癌/帕妥珠单抗/含蒽环类化疗方案/HER2阳性乳腺癌/安全性
Key words
Antibodies,monoclonal/Anthracyclines/Breast cancer/Patuzumab/Anthracycline containing chemotherapy regimen/HER2 positive breast cancer/Safety
维普
万方数据